Amy D Shapiro
Overview
Explore the profile of Amy D Shapiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1603
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lewandowska M, Nasr S, Shapiro A
J Blood Med
. 2025 Feb;
16:95-115.
PMID: 39995897
In recent years, gene therapy and bio-engineered hemostatic molecules have revolutionized treatment for people with hemophilia. These innovative therapies aim to decrease treatment burden and improve patient quality of life....
2.
Escobar M, Hoffman M, Castaman G, Hermans C, Mahlangu J, Oldenburg J, et al.
Res Pract Thromb Haemost
. 2025 Feb;
9(1):102670.
PMID: 39990097
Management of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa). Two rFVIIa products are commercially approved for use in the...
3.
Gupta S, Bunce M, Cid E, Camire R, Shapiro A
Res Pract Thromb Haemost
. 2025 Jan;
9(1):102646.
PMID: 39810984
Background: The development of acquired factor (F)V with inhibitor (AFVwI) is rare, resulting mainly in bleeding complications, although sporadic cases of thrombosis in adults have been reported. Key Clinical Question:...
4.
Lewandowska M, Gordon S, Betbadal A, Shapiro A
J Thromb Haemost
. 2024 Oct;
23(2):525-530.
PMID: 39454885
Background: Hereditary hemorrhagic telangiectasia (HHT) is a bleeding disorder characterized by arteriovenous malformations, commonly presenting with epistaxis and gastrointestinal (GI) bleeding. Bleeding symptoms may be difficult to manage and may...
5.
Nakar C, McDaniel H, Parker J, Thibaudeau K, Thukral N, Shapiro A
Front Pediatr
. 2024 Oct;
12:1465166.
PMID: 39372655
Plasminogen deficiency type 1 (PLGD-1, hypoplasminogenemia) is an ultra-rare, lifelong disease associated with development of fibrinous lesions in multiple organ systems. Depending on lesion location, clinical manifestations of PLGD-1 can...
6.
Cuker A, Kavakli K, Frenzel L, Wang J, Astermark J, Cerqueira M, et al.
N Engl J Med
. 2024 Sep;
391(12):1108-1118.
PMID: 39321362
Background: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase...
7.
Ljung R, Matino D, Shapiro A
Eur J Haematol
. 2024 Feb;
112(5):678-691.
PMID: 38369860
Current hemophilia B treatment guidelines recommend routine prophylaxis with factor IX (FIX) replacement products, tailored to maintain plasma activity at levels that will prevent bleeds. However, plasma FIX activity may...
8.
Olasupo O, Nakar C, Haddix C, Matthew T, Matino D, Malec L, et al.
Res Pract Thromb Haemost
. 2023 Dec;
7(7):102228.
PMID: 38077822
Background: The development of antibodies (inhibitors) to clotting factors compromises the management of hemophilia A and B, resulting in resistance to clotting factor replacement and, in many cases, the need...
9.
Alvarez-Roman M, Shapiro A, Ragni M, Palmborg H, Bystricka L, Szamosi J, et al.
Res Pract Thromb Haemost
. 2023 Sep;
7(6):102163.
PMID: 37720484
Background: Prophylactic factor replacement therapy is recommended over on-demand treatment for preserving long-term joint health in hemophilia. Extended half-life products, including efmoroctocog alfa/eftrenonacog alfa (recombinant factor VIII [FVIII]/FIX Fc fusion...
10.
Shapiro A, Chambost H, Ozelo M, Falk A, Ahlin H, Casiano S, et al.
Res Pract Thromb Haemost
. 2023 Sep;
7(6):102169.
PMID: 37694269
Background: Major surgical procedures are associated with significant bleeding risk and infectious complications in patients with hemophilia, which may be minimized by factor replacement. Monitoring perioperative factor levels guides dosing...